%20(2000%20x%201380%20px)-2.png)
Our mission is to ACCELERATE BREAKTHROUGHS in metastatic breast cancer (mBC) by placing research at the heart of the conversation.
We exist to AMPLIFY THE VOICES of the metastatic patient community and highlight the URGENT NEED for innovative, life-extending and LIFE-SAVING TREATMENTS.
Thanks to a generous private donor, every single dollar donated goes directly to fund mBC research.
FOR PATIENTS. BY PATIENTS.
2026 NYFW Still
What we are funding,
TOGETHER.
Penn Medicine / Abramson Cancer Center – Rena Rowan Breast Center: Development of a multidisciplinary Invasive Lobular Breast Cancer (ILC) Research Working Group. This is especially aimed at strengthening research infrastructure and collaboration around lobular breast cancer, an area MBCure identifies as understudied. Penn’s MBCure liaison, Dr. Rachel Jankowitz, specializes in invasive lobular carcinoma.
Memorial Sloan Kettering: HERizon-Breast, a Phase II clinical trial for newly diagnosed HER2-positive metastatic breast cancer led by Dr. Pedram Razavi. It uses highly sensitive circulating tumor DNA (ctDNA) testing plus imaging to guide sequential HER2-directed treatment, with the explicit aim of achieving long-term remission and potentially curing a subset of patients. The study also incorporates local treatment and strategies intended to prevent CNS/brain recurrence. It is currently recruiting.
Fox Chase Cancer Center: Development of a lobular and triple-negative breast cancer database, creating a research resource around two areas where metastatic disease still has major unmet needs. And in collaboration with Temple:
Triple-negative breast cancer dormant-metastases research with Lucia Borriello, PhD. This work is focused on the biology of metastatic dormancy—the cancer cells that can remain hidden or inactive and later reawaken to cause metastatic disease.
Why We Fund MBC Research
BREAST CANCER is a global epidemic, killing 42,170* women a year and about 500 men, in the US alone. 670,000 worldwide.
99% OF THOSE DEATHS* ARE A RESULT OF STAGE IV DISEASE. DESPITE THIS, MBC STILL RECEIVES THE LEAST AMOUNT OF FUNDING.
*American Cancer Society , WHO, & BCRF
Breast cancer affects all women, but not all women are affected equally. Black women have a 40% greater risk of dying from the disease.
RACIAL AND ETHNIC DISPARITIES IN DIAGNOSIS, TREATMENT, AND OUTCOMES CONTINUE TO PUT NON-WHITE WOMEN, PARTICULARLY BLACK WOMEN.
We're here for the real ones, the loud
ones and the unapologetically
passionate ones. This is a true patient-powered movement, so if you're down
to disrupt, speak truth, and flip the
script on breast cancer advocacy, we
want to work with you.
Individual, crew, brand, it doesn't
matter... If your heart's in it, LET'S GO!
Honoring our late friend and founder, Champagne Joy.
Our mission is made possible by our generous co-conspirators:
